Related references
Note: Only part of the references are listed.Ipilimumab safety profile: Summary of findings from completed trials in advanced melanoma.
R. A. Ibrahim et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates
Caroline Jochems et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
CTLA-4 polymorphisms and susceptibility to inflammatory bowel disease: A meta-analysis
Young Ho Lee et al.
HUMAN IMMUNOLOGY (2014)
Association of CTIA-4 variants with susceptibility to inflammatory bowel disease: A meta-analysis
Min Zhang et al.
HUMAN IMMUNOLOGY (2014)
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
Eugene D. Kwon et al.
LANCET ONCOLOGY (2014)
Ipilimumab-Associated Colitis: CT Findings
Kyung Won Kim et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2013)
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial
M. Reck et al.
ANNALS OF ONCOLOGY (2013)
Lymphocytic Colitis Secondary to Ipilimumab Treatment
Alejandro Garcia-Varona et al.
INFLAMMATORY BOWEL DISEASES (2013)
Ipilimumab-induced Perforating Colitis
Kisha A. Mitchell et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2013)
Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events
Vafa Shahabi et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Ipilimumab-induced acute severe colitis treated by infliximab
Cecile Pages et al.
MELANOMA RESEARCH (2013)
CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
Peter A. Prieto et al.
CLINICAL CANCER RESEARCH (2012)
Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab is associated with a profound long-lasting depletion of Foxp3+regulatory T cells: A mechanistic explanation for ipilimumab-induced severe enterocolitis?
S. Nancey et al.
INFLAMMATORY BOWEL DISEASES (2012)
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
Alfons J. M. van den Eertwegh et al.
LANCET ONCOLOGY (2012)
Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer
Grazia Graziani et al.
PHARMACOLOGICAL RESEARCH (2012)
Colitis associated with biological agents
Hugh James Freeman
WORLD JOURNAL OF GASTROENTEROLOGY (2012)
Characteristics and management of immune-related adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma
Stephanie Andrews et al.
Cancer Management and Research (2012)
TNF ALPHA ANTAGONIST THERAPY and safety monitoring
Thao Pham et al.
JOINT BONE SPINE (2011)
Association of cytotoxic T lymphocyte associated antigen-4 gene (rs60872763) polymorphism with Crohn's disease and high levels of serum sCTLA-4 in Crohn's disease
Zhitao Chen et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Releasing the Brake on the Immune System: Ipilimumab in Melanoma and Other Tumors
Ahmad Tarhini et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2010)
Refractory Colitis Following Anti-CTLA4 Antibody Therapy: Analysis of Mucosal FOXP3+ T Cells
James D. Lord et al.
DIGESTIVE DISEASES AND SCIENCES (2010)
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
Jedd D. Wolchok et al.
LANCET ONCOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Infliximab in the Treatment of Anti-CTLA4 Antibody (Ipilimumab) Induced Immune-Related Colitis
David R. Minor et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2009)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
Jeffrey Weber et al.
CLINICAL CANCER RESEARCH (2009)
Cytotoxic T-Lymphocyte-Associated Antigen 4 Antibody-Induced Colitis and Its Management with Infliximab
R. L. Johnston et al.
DIGESTIVE DISEASES AND SCIENCES (2009)
α-CTLA-4 mAb-associated panenteritis -: A histologic and immunohistochemical analysis
Darryl A. Oble et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2008)
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade
Stephanie G. Downey et al.
CLINICAL CANCER RESEARCH (2007)
Review: Anti-CTLA-4 antibody ipilimumab: Case studies of clinical response and immune-related adverse events
Jeffrey Weber
ONCOLOGIST (2007)
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer
Eric J. Small et al.
CLINICAL CANCER RESEARCH (2007)
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4
Kimberly E. Beck et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy
KS Peggs et al.
CURRENT OPINION IN IMMUNOLOGY (2006)
Infliximab as rescue therapy in severe to moderately severe ulcerative colitis:: A randomized, placebo-controlled study
G Järnerot et al.
GASTROENTEROLOGY (2005)
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
FS Hodi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma
CM Balch et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
